Non-radioactive T3S Immunoassay and Scalable Sulfation Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale production of 3,5-diiodo-O-[3-iodo-4-(sulfooxy)phenyl]-L-tyrosine (T3S) face challenges in scalability and purification, and existing assays for detecting T3S levels in serum rely on radioactive reagents, which are unsafe and impractical for clinical and research use.
Innovation Solution
A process for preparing a mono-cationic salt of T3S through sulfation with chlorosulfonic acid in dimethylacetamide, followed by salification, and the development of non-radioactive immunoassays such as competitive ELISA and Lanthanide Fluorescence Immuno-Assay for detection and quantitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radioactive reagents are used for T3S detection, then measurement sensitivity is improved, but safety and practicality deteriorate
Solution Approach 1:
The patent replaces expensive and hazardous radioactive reagents with safer, non-radioactive alternatives such as enzyme-conjugated antibodies (HRP, alkaline phosphatase) and fluorescent labels. These alternative reagents achieve comparable or superior detection sensitivity without the safety concerns associated with radioactivity, making the assay practical for routine clinical and research use.
Solution Approach 2:
The patent substitutes the radioactive detection mechanism with non-radioactive detection systems, including enzyme-linked immunosorbent assay (ELISA) and fluorescent immunoassays. This replacement maintains measurement capability while eliminating harmful radiation, enabling safe and effective T3S detection in clinical and research settings.
2Productivity
If conventional sulfation methods are used for large-scale T3S production, then production quantity is improved, but purification difficulty and product quality deteriorate
Solution Approach 1:
The patent introduces dimethylacetamide (DMAC) as an intermediary solvent that facilitates the sulfation reaction between T3 and chlorosulfonic acid. DMAC enables efficient sulfation while allowing for straightforward purification through filtration and recrystallization, achieving both high production quantity and high product purity (>95%) in a scalable manner.
Solution Approach 2:
The patent optimizes reaction parameters including temperature control (0-10°C), reagent ratios (CSA:T3 = 5:1 to 10:1), and reaction time to maximize T3S yield while maintaining purity. These parameter optimizations enable large-scale production with consistent high-quality output, resolving the contradiction between quantity and quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enables the production of T3S in high purity and quantity suitable for clinical use, and the non-radioactive assays provide a safer and effective means for detecting T3S levels, overcoming the limitations of previous methods.
Implementation Method 1
sulfation of the compound of formula I with chlorosulfonic acid (CSA) in the presence of dimethylacetamide (DMAC) as a sovent
Implementation Method 2
non-radioactive immunoassays such as competitive ELISA and Lanthanide Fluorescence Immuno-Assay for detection and quantitation
Implementation Method 3
Lanthanide Fluorescence Immuno-Assay for detection and quantitation
Data Source
Figure 1a~1b
Figure 2
AI summary
The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.